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American College of Cardiology FoundationPulmonary hypertension (PH) is a progressive and irre-
versible disorder eventually resulting in right ventricular
(RV) failure and death. Despite advances in the treatment of
PH, the overall prognosis remains poor, with an approxi-
mate annual mortality rate of 11.8% in patients with idio-
pathic pulmonary arterial hypertension (IPAH), and 16.6%
in those diagnosed with scleroderma-related PH (1).
Heart-lung transplantation (HLTx) and bilateral lung
transplantation (BLTx) remain the ﬁnal options for patients
with PH remaining in New York Heart Association
(NYHA) functional class III/IV despite combination ther-
apy. Patients in NYHA functional class IV or who remain in
functional class III despite combination therapy should be
referred early to a PH center of excellence or other tertiary
center for transplantation assessment. Predictors of survival
after lung transplantation include the 6-min walk distance
(6MWD) and peak myocardial oxygen consumption, right
atrial pressure (RAP) >15 mm Hg, and a cardiac in-
dex <2.0 l/min/m2 (2).
BLTx is the operation of choice for patients with IPAH
and those with severe secondary PH, as single-lung trans-
plant has an increased risk of perioperative allograft edema
(3). In patients with congenital cardiac abnormalities,
particularly Eisenmenger syndrome, and severe right and/or
left heart dysfunction, HLTx provides survival advantages
and may be considered the procedure of choice (4,5). In
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vember 11, 2013.BLTx depends on individual center choice and policy and
donor availability. Overall survival rates of BLTx and HLTx
are similar; however, freedom from obliterative bronchiolitis–
related death has been reported to be signiﬁcantly greater in
the latter (6). After transplantation, there is an immediate
decrease in pulmonary artery pressure (PAP) and RV size
and normalization of septal geometry (7). Unadjusted
3-month mortality is highest in patients with PH pre-
transplantation (8). However, among those surviving at
least 1 year, better conditional half-lives after transplantation
occur in patients with PAH (10 years) compared with pa-
tients with other underlying diagnoses such as chronic
obstructive pulmonary disease or idiopathic pulmonary
ﬁbrosis (6.8 years for both) (8). Heart-lung transplant re-
cipients with Eisenmenger syndrome and IPAH have
signiﬁcantly better overall survival than patients with other
congenital abnormalities (8). After 1-year survival post-
transplantation, long-term survival rates are relatively good,
and w50% of patients remain alive >9 years after trans-
plantation (8).
Unfortunately, lung transplantation is only a viable option
in approximately one-third of patients with PAH referred
for lung transplantation (9). This paper describes both
established and novel percutaneous interventional tech-
niques that may palliate symptoms or serve as a bridge to
transplantation in selected patients with PH.Atrial Septostomy
Atrial septostomy (AS) is indicated in some patients with
RV failure and associated PH in whom medical therapy has
failed. It should only be attempted in centers with extensive
experience in managing patients with PAH and lung trans-
plantation. ASmay be used as a bridge to lung transplantation
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612or as a therapy where there is
limited access to lung donors. Se-
vere IPAH has been the main
indication for AS in adults, but
other common indications include
PAH associated with congenitally
corrected heart disease, connec-
tive tissue disease, and distal
chronic thromboembolic PH (10).
The principle of AS is based
on the observation that patients
with Eisenmenger syndrome have
a better prognosis than those with
IPAH (11). The physiological
basis for improvements after AS
include an improved cardiac out-
put, RV decompression, and redu-
ced sympathetic over-reactivity.
An iatrogenic atrial septal defect
improves left ventricular pre-load,
thereby improving cardiac output.
The decrease in systemic arter-
ial oxygen saturation induced by
right–left shunting is compensated
for by an increase in cardiac output
(2,12–19). Improvements in RV
function afterAShave been shown
using echocardiography (20) and
inferred using serial B-type natri-
uretic peptide (BNP) levels (21).
AS has been shown to have
a beneﬁcial effect on reducing
sympathetic nervous activation
as measured by muscle sympa-
thetic nerve activity (MSNA)Figure 1
The Diabolo Fenestrated Stent Technique for
Mounting a Stent
(A) A loop of deﬁned diameter is created using a temporary pacing wire. This is
placed over a standard balloon valvuloplasty catheter. (B) The stent, mounted and
crimped with the loop centered. (C) The stent is placed across the fenestration,
and the balloon catheter is fully inﬂated. Reprinted with permission from Stümper
et al. (27).(22,23). After AS, hemodynamic beneﬁts have been shown to
translate into functional beneﬁts including improvements in
6MWD and NYHA functional class (2,19).
Technique. The creation of the interatrial opening was
originally achieved by balloon AS, whereby an inﬂated
balloon was forcefully jerked/pulled across the foramen ovale
to tear the atrial septum and promote interatrial mixing of
blood. As an alternative to balloon AS, balloon-dilated AS
has been developed in which the atrial septum is punctured
using a Brockenbrough needle (multiple manufacturers), and
the interatrial opening is progressively dilated with
increasing balloon size (24). This allows the size of the
defect to be gradually increased, taking care to ensure arterial
oxygen saturation does not decrease >10% and that left
ventricular end-diastolic pressure does not increase to
>18 mm Hg.
After balloon-dilated AS, the interatrial opening
commonly closes, but repeated procedures can be performed
with varying degrees of success. Fenestrated devices
(or modiﬁed techniques of stent fenestration) have also been
used to control the degree of shunt created and to maintainthe patency of the interatrial opening (25–27). The diabolo-
shaped stent improved symptoms and was free of thrombotic
complications in selected small studies (26,27). The stents
used were mounted on a standard valvuloplasty balloon
catheter that was constricted by a loop using a temporary
pacing wire (Fig. 1). Full balloon inﬂation resulted in a
diabolo-shaped stent conﬁguration (Fig. 2). The stent can be
further dilated or constricted to increase or reduce the degree
of shunting. Another approach using fenestrated devices has
been the use of modiﬁed Amplatzer septal occluder devices
(Fig. 3). However, these devices have a higher rate of
thrombotic occlusion (25).
The timing of AS to achieve optimal beneﬁt is uncertain.
In the majority of cases, AS has been performed after failure
of optimal medical therapy as a last resort before lung
transplantation. However, one study suggested that patients
receiving concomitant medical therapy after AS had a higher
survival rate than patients who received AS alone (19).
Limitations of that study include its retrospective nature and
the fact that it did not include a subgroup of patients who
received only IPAH-speciﬁc pharmacological therapy. It is
possible that IPAH-speciﬁc pharmacological therapy would
have resulted in an outcome similar to that achieved in the
AS/medical therapy group. The 1-month mortality rate
was only 2%, which may be due to the fact that approxi-
mately one-third of the patient group underwent AS early
in the course of their disease (RV end-diastolic pressure
<10 mm Hg). The same favorable outcome was found in a
series of young children who underwent AS at a relatively
early stage of their disease (mean RAP of 9  5 mm Hg and
syncope rather than overt right heart failure) (28). Never-
theless, it does seem intuitive that the combination of PAH-
speciﬁc therapies in conjunction with AS in patients earlier
Figure 2 Final Position of the Stent Across the Atrial Septum
The stent can then be further dilated or constricted depending on the patient’s hemodynamics. Reprinted with permission from Stümper et al. (27).
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613in the course of their disease may offer a survival advantage
rather than using AS in the latter stages of disease. The
timing of AS should occur before the development of
RAP 20 mm Hg, left ventricular end-diastolic pressure
>18 mmHg, pulmonary vascular resistance index>55 U/m2,
or baseline O2 saturations <90% in room air, as these factors
have been shown to be predictive of a 25% procedural
mortality rate (2,17).Figure 3 Modiﬁed Standard Amplatzer Atrial Septal Occluder With S
Reprinted with permission from Lammers et al. (25).Complications and survival. Procedural complications
include balloon rupture and embolization of balloon frag-
ments, cardiac perforation or damage including rupture of
the atrial appendage, failure to deﬂate the balloon, stroke,
and vascular complications (29). Patients with severe right
heart failure and extremely high pulmonary pressures do
not tolerate AS because massive right-to-left shunting may
result in severe systemic arterial oxygen desaturation andelf-Made Fenestration
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614hypoxia leading to ischemia and death. The risk of death is
higher for patients with advanced disease, but these are the
patients thought to beneﬁt most from the procedure (2,30).
Immediate mortality rates after AS vary from 0% to 20%,
with 30-day mortality rates as high as 23% (15,30). The
mean survival medium term after AS (excluding procedural
deaths) has been shown to be 63.1 months (2). Most
studies have compared the effect of AS on survival by
comparing survival rates post-procedure with survival rates
as predicted by the regression equation obtained from the
IPAH registry of the U.S. National Institutes of Health
(31). The limitations to this approach are that the charac-
teristics of the population studied in the registry were very
different from those in patients undergoing AS. For example,
all National Institutes of Health–enrolled patients had
IPAH, and no patients were included with secondary causes
of PH. Less than 50% of these patients were taking long-term
anticoagulation, and none received advanced disease-
targeting therapies. Consequently, using the National In-
stitutes of Health equation could potentially underestimate
survival rates and overstate the potential beneﬁts of AS on
survival.
Pott’s Shunt
An alternative method of decompressing the right ventricle
is by forming a direct anastomosis between the descending
aorta (dAo) and the left pulmonary artery (LPA), a Pott’s
shunt (32). This offers several theoretical advantages over
the creation of an AS. Blood is shunted directly into the
dAo, which avoids exposing the brain and myocardium to
desaturated blood. A Pott’s shunt may offer more reliable
shunting than would an atrial septal defect by addressing
suprasystemic pulmonary artery surges. Furthermore, un-
controlled hypoxemia can be potentially avoided by the use
of a pressure-restrictive shunt. The largest experience
described in the literature is a series of 8 children, all of
whom were in NYHA/World Health Organization func-
tional class IV with symptoms of repeated syncope or signs
of right heart failure (32). Six of 8 patients survived and
remained well at a mean follow-up of 63 months, with
improvements in RV dimensions on echocardiography,
improved functional status, as well as lower BNP levels.
Transcatheter creation of an aortopulmonary shunt has
been successfully performed in animals (33) and more
recently in humans (34). Ten piglets had a Pott’s shunt
created by radiofrequency perforation from the aorta to the
pulmonary trunk, followed by stent implantation (bare-
metal stents or polytetraﬂuoroethylene-covered coronary
stents). Oxygen saturation improved from 63% (range 53%
to 72%) in the right atrium to 84% (range 59% to 92%) in
the pulmonary artery (p < 0.005). At follow-up, 4 of 6 stents
were obstructed because of tissue ingrowth in the bare-metal
stents and thrombus formation in the covered stents.
Percutaneous aortopulmonary shunt formation was also
reported in a series of 4 adults (34) in whom a modiﬁedBrockenbrough needle and the “stiff” end of a 0.014-inch
wire were used to puncture the dAo and LPA. After
balloon dilation, an iCAST 7  22-mm covered stents
(Atrium Medical Corporation, Hudson, New Hampshire)
spanning the LPA and dAo walls was implanted. Follow-up
was limited to 4 to 10 months. This technique is very high
risk, as any misjudgment in stent length to span the distance
between the LPA and dAo can result in hemorrhage. One
patient died 8 days post-procedure of pneumonia and
multiorgan failure, and 1 died of catastrophic intrathoracic
bleeding.
Another group described 3 patients with IPAH and se-
vere PH who had a small patent ductus arteriosus or probe-
patent patent ductus arteriosus (35). This allowed insertion
of a stent to provide a communication between the dAo and
LPA. The stent size used varied from 6 to 9 mm in diameter
and was gradually dilated to equalize PAP and aortic pres-
sure. After a mean follow-up of 14  9 months, all 3 pa-
tients showed improved functional capacity and improved
RV function. Importantly, there were no major complica-
tions or deaths.
Both of the series described were small but indicate a
possible role for intervention as an additional therapy in an
already difﬁcult to-treat group of patients. After a stent
anastomosis is created, there is the possibility that it could be
further dilated to increase the degree of shunting. At pre-
sent, these techniques are experimental and will require
larger numbers of patients with longer follow-up periods to
determine their full effects on survival. The optimal timing
of the percutaneous Pott’s shunt is yet to be determined. It
currently appears to be high risk and should be reserved
for patients in whom AS or lung transplantation is
contraindicated.
Segmental Balloon Pulmonary Angioplasty for
Treatment of CTEPH
Pulmonary endarterectomy (PEA) is the deﬁnitive treat-
ment for chronic thromboembolic pulmonary hypertension
(CTEPH), with operative mortality rates reported as 4% to
7% and 5-year survival rates of 90% at centers of excellence
(36). However, it is contraindicated in the presence of severe
underlying lung disease (37). Lesions located in distal arte-
rioles are often inaccessible and are associated with higher
operative mortality rates (36). Furthermore, as many as 30%
of patients continue to have residual PH post-PEA.
Although this appears not to have a signiﬁcant effect on
mortality, it is associated with reduced exercise capacity and
lower objective measures of quality of life such as physical
function, general health, and emotional well-being (38,39).
Medical therapy may play a role in the subset of patients
who are not suitable for PEA. The BENEFiT (Bosentan
Effects in iNopErable Forms of chronIc Thromboembolic
pulmonary hypertension) study randomized inoperable or
persistent CTEPH patients to bosentan or placebo (40).
After 16 weeks of treatment with bosentan, there was a
JACC Vol. 63, No. 7, 2014 Bhamra-Ariza et al.
February 25, 2014:611–8 Interventional Therapy for Severe PAH
61524% reduction in peripheral vascular resistance (146
dyn$s$cm5; p < 0.0001) compared with placebo, but with
no signiﬁcant difference in 6MWD or improvement in
NYHA functional class status between the 2 groups.
Balloon angioplasty of the pulmonary artery (BPA) has
also been used with encouraging results in adult patients
with CTEPH in whom distal disease is inaccessible and too
high risk (41–44). Physiologically, it improves pulmonary
blood ﬂow distribution and increases pulmonary vascular
capacitance, decreasing RV afterload. Feinstein et al. (43)
performed BPA in 18 patients with CTEPH who were
poor surgical candidates because of either medical comor-
bidities or surgically inaccessible disease. Pulmonary artery
stenoses were gradually dilated using balloons that were
sized to be 75% to 100% of the vessel diameter. This is in
contrast to previous BPA experience in congenital patients
in whom a larger ratio of balloon to minimal luminal
diameter was preferred (45). This resulted in clear im-
provements in NYHA functional class, 6MWD, and mean
PAP. Repeat angiography demonstrated that all previously
treated vessels remained patent at 1 to 40 months after initial
BPA.
Kataoka et al. (44) investigated the effects of BPA in 29
patients with CTEPH. An older cohort was used in this
study: 37% of patients were >70 years of age compared with
11% in the study by Feinstein et al. (43). Rather than all
patients being inoperable, an undisclosed number of patients
had thromboembolic disease that was amenable to PEA, and
3 patients had residual PH after previous PEA. The majority
of patients were receiving advanced medical therapies.
Interestingly, BPA did not result in any immediate hemo-
dynamic effect, conﬁrming that a certain amount of time is
required for positive remodeling of the pulmonary vascula-
ture, as seen in PEA (2). Right heart catheterization at 6
months demonstrated signiﬁcant improvements in hemo-
dynamic parameters as well as signiﬁcant improvements in
functional exercise capacity and BNP levels. Unfortunately,
follow-up was for only 6 months, and so no conclusions can
be made about the impact of BPA on long-term survival.
Mizoguchi et al. (42) performed BPA in 68 subjects, all
of whom had surgically inoperable CTEPH. All patients
showed signiﬁcant improvements in PAP, BNP levels, and
functional exercise capacity. One patient died of right heart
failure 28 days after BPA, another died of pneumonia, and
the remaining 66 patients are alive at 2.2  1.4 years.
Follow-up at 1 year conﬁrmed normalized PAP and
improved angiographic appearance of the pulmonary
arteries.
Reperfusion pulmonary injury can be a fatal complication
that occurs with a reported incidence as high as 68% after
BPA compared with 10% to 15% after PEA (41–44,46).
Increased local pulmonary blood ﬂow and pressure in a
previously underperfused vascular bed cause an acute in-
crease in capillary perfusion pressure. Strategies to reduce
reperfusion edema include limiting dilation to no more than
2 vessels per sitting (42), the use of pharmacological agentsbefore BPA (42,43), and intrapulmonary imaging to reduce
the risk of reperfusion pulmonary injury and rupture of the
pulmonary artery. Intravascular ultrasound and optical
coherence tomography have been used to determine optimal
balloon size for dilation of pulmonary vessels (41,42).
Although a small balloon was used for the initial dilation to
avoid rupture and dissection of the pulmonary artery, further
dilation was based on intravascular ultrasound sizing using
the vessel diameter, ensuring that the maximal size is not
>90% of the original size of the vessel diameter. These
techniques do result in detailed anatomic images; however,
in the absence of a control group, it is difﬁcult to determine
whether these techniques are helpful.
Once CTEPH has been diagnosed, patients should be
referred for surgical evaluation by an experienced multidis-
ciplinary team (2). In candidates found to be unsuitable for
PEA, BPA can be considered an alternative, providing that
the unit has the appropriate expertise. The timing of this
procedure is similar to that of patients awaiting PEA (i.e.,
patients should be referred for assessment with a resting
pulmonary vascular resistance of at least 300 dyn$s$cm5, or
w4 Wood units) (47).
Pulmonary Artery Vasoconstriction
and Denervation
Pulmonary artery denervation (PADN) is a novel technique
under investigation as a treatment for PH. It is thought to
work by reducing sympathetic stimulation of the pulmonary
vasculature. The mechanisms for increased sympathetic
activation are not clear, but comparisons have been made with
chronic heart failure and associated activation of the renin-
angiotensin-aldosterone system (48,49). In addition, hypox-
ia within the pulmonary arteries is thought to lead
to enhanced transcription of b1-adrenoreceptor messenger
ribonucleic acid, with resultant increases in b1-adrenoreceptor
expression on pulmonary blood vessels (50). Chronic levels of
adrenergic excitation have been shown to adversely affect
RV modeling. In an animal model of RV heart failure caused
by pulmonary artery banding, adrenergic b-receptor density
was reduced compared with control animals in the stressed
right ventricle (51). In human subjects affected by primary
PH, it has been shown that the b-receptor number is
reduced only in the failing right ventricles, conﬁrming that
b-receptor down-regulation is chamber speciﬁc (52). The up-
regulation of a1-adrenoreceptors and reduction of adrenergic
b-receptors is likely to lead to vasoconstriction rather than
vasodilation of the pulmonary vasculature.
Sympathetic nervous system activity has been assessed
indirectly by using peroneal nerve microneurography. This
has conﬁrmed that PH patients have increased levels of
sympathetic activity as demonstrated by higher MSNA
(23). Furthermore, in PH patients post-AS, MSNA levels
have been shown to decrease compared with control pa-
tients, implying that AS decreases sympathetic hyperactiv-
ity. The decrease in MSNA was directly related to the
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616decrease in RAP, suggesting that sympathetic overactivity
in patients with severe PAH is related to right atrial
distension (22).
Previous investigations have shown that distention and
occlusion of 1 branch of the pulmonary artery results in an
increase in pulmonary vascular pressure and resistance
(53,54). This increase occurs in the absence of any signiﬁ-
cant change in RV or left ventricular end-diastolic pressure,
aortic pressure, and cardiac output. It is postulated that
baroreceptors are situated close to the bifurcation of the
main pulmonary artery and are involved in facilitating a
neural reﬂex as a result of activation by stretch receptors (54).
In animal studies, dissection of the areas of the pulmonary
artery under the bifurcation prevented the increase in
vascular resistance response to balloon inﬂation. Further-
more, there was no effect of breathing 100% oxygen on PAP
during pulmonary artery distention, suggesting that hypoxia
was not the principal cause of observed pulmonary vaso-
constriction (53). It is unlikely that the parasympathetic
nervous system is involved in this reﬂex because vagotomy
does not have any effect on pulmonary vascular resistance
after balloon inﬂation (53).
Based on these experiments and the development of
renal denervation as a treatment for drug-resistant hyper-
tension (55), percutaneous PADN was performed in a dog
model (56). Preliminary experiments (not published by the
group) suggested that catheter ablation <2 mm proximal to
the bifurcation of the main pulmonary artery was the most
effective area for PADN. Occlusion of the left pulmonary
interlobar artery by balloon inﬂation induced signiﬁcant
increases in PAP and RV pressure, which persisted for
10 min. Hemodynamic parameters induced by interlobar
artery occlusion returned to baseline after PADN. The
authors acknowledge that the gradual increase in inﬂation
pressure itself could induce vasoconstriction and increase
PAP, and they were unable to provide histological evidence
of the effects of catheter ablation. PADN was demon-
strated to abolish acute PH, but its effect on long-term
causes of PH are not known. Furthermore, it is not
known whether the effect of PADN is permanent because
it has been shown in rats that sympathetic nerve reinner-
vation can occur (57).
A small ﬁrst-in-humans study consisting of 21 patients
with IPAH reported signiﬁcant improvements in mean PAP
after PADN (58). In addition, signiﬁcant improvements in
functional capacity and NYHA functional class were noted
in subjects who underwent PADN. Limitations include the
lack of randomization between control subjects and those
undergoing PADN. Subjects were only followed for
3 months, and therefore, the long-term results of this
treatment cannot be determined. PADN has only been
performed in a small number of patients with IPAH who,
despite being refractory to medical therapy, had normal
RAPs, thus casting doubt on the severity of PH in the
treatment group (58). It is, therefore, difﬁcult to make any
recommendations about the optimal timing of this very newtechnique because the efﬁcacy remains to be proved in larger
randomized, controlled trials.
Conclusions
Advances in medicine have improved the prognosis of pa-
tients with severe PH. However, there continues to be a
subset of patients who may beneﬁt from procedures that
decompress the right ventricle. These techniques are highly
specialized, and patients should be referred to specialist
centers with expertise in PH and lung transplantation. The
optimal timing of AS has yet to be determined, but obser-
vational data suggest that the combination of PAH-speciﬁc
therapies in conjunction with AS in patients earlier in the
course of their disease may offer a survival beneﬁt rather than
performing AS in the latter stages of their disease. Modi-
ﬁcation of AS techniques, such as those using modiﬁed
fenestrated stents, may offer the possibility of increasing or
decreasing the shunt at a later date and tailoring individu-
alization of therapy in these very ill patients. Transcatheter
Pott’s shunt creation is highly challenging and so far has
only been performed in a handful of subjects. Further re-
ﬁnements in the technique are required before it is consid-
ered a safe procedure. Nevertheless, it may obviate the need
for thoracotomy and sternotomy in these high-risk patients.
BPA, although technically challenging, has been shown to
be an efﬁcacious treatment for patients with CTPEH who
have surgically inaccessible disease, albeit with a high inci-
dence of reperfusion edema. Limiting the intervention to no
more than 2 arteries per setting seems to be the most suc-
cessful method of reducing the incidence of this complica-
tion. However, long-term and randomized, controlled trial
data for both BPA and AS are not yet available. Results
from PADN are still very preliminary, and the mechanisms
of action are still not fully understood. However, it does
provide an interesting alternative future approach to read-
dressing the balance between vasoconstriction and vasodi-
lation of the pulmonary vasculature.
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